Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI (ESKETAM)

This observational trial (n=13) was conducted by the University Hospital, Strasbourg, France. The study aimed to assess the tolerance and potential synergistic effect of combining intranasal esketamine with non-selective MAOIs in patients with depression and anxiety disorders.

The study involved a retrospective analysis of files from patients who had been treated with intranasal esketamine between January 1, 2018, and March 31, 2022.

The primary outcome measure was the number of adverse events for each patient during the specified period. The trial enrolled 13 participants who met the inclusion criteria of being major subjects treated with intranasal esketamine within the specified timeframe and not objecting to the reuse of their data for scientific research purposes.

The study, which started on April 11, 2022, and completed on December 11, 2022, was designed as an observational case-only study with a retrospective time perspective. It was conducted at the Service de physiologie – Explorations fonctionnelles – CHU de Strasbourg, France.

Topic Depression Anxiety
Compound Ketamine
Country France
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.